Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Precise Research Centers

Neither a doctor nor a teaching hospital

Research payments

$310,855

105 payments

Through program year 2025, Precise Research Centers is reported as receiving $310,855 in research payments, across 105 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $7,340 20
2024 Research $34,925 4
2023 Research $96,118 18
2022 Research $58,089 38
2021 Research $99,228 10
2020 Research $1,356 9
2019 Research $13,800 6

Breakdown

Who paid Research payments · program years 2019–2025
  1. Alkermes, Inc. $134,970 30 payments
  2. Hoffmann-La Roche Limited $114,199 7 payments
  3. LivaNova USA, Inc. $46,375 34 payments
  4. Genentech, Inc. $12,885 4 payments
  5. Boehringer Ingelheim Pharma GmbH & Co.KG $1,273 8 payments
  6. Sunovion Pharmaceuticals Inc. $620 12 payments
  7. Sumitomo Pharma America, Inc. $450 9 payments
  8. Boehringer Ingelheim International GmbH $83 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Taar1 4 for Negative Symptoms $114,199 7 payments
  2. A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder $60,321 21 payments
  3. A Phase 3 Study to Evaluate Weight Gain of ALKS 3831 Compared to OLANZAPINE in Adults with Schizophrenia $34,300 1 payment
  4. A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression $26,100 6 payments
  5. A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia $25,852 1 payment
  6. A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia $13,736 3 payments
  7. Postgraduate Roll Over Study $12,885 4 payments
  8. Recover $7,340 20 payments
  9. The RECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes $7,314 4 payments
  10. A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) $5,621 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record